Conclusions:Ivosidenib and azacitidine showed significant clinical benefit as compared with placebo and azacitidine in this difficult-to-treat *** neutropenia and infections were less frequent in the ivosidenib-and-az...
详细信息
Conclusions:Ivosidenib and azacitidine showed significant clinical benefit as compared with placebo and azacitidine in this difficult-to-treat *** neutropenia and infections were less frequent in the ivosidenib-and-azacitidine group than in the placebo-and-azacitidine group,whereas neutropenia and bleeding were more frequent in the ivosidenib-and-azacitidine group.(Funded by Agios Pharmaceuticals and Servier Pharmaceuticals;AGILE *** number,NCT03173248.).
暂无评论